Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
Am J Ophthalmol
; 227: 116-124, 2021 07.
Article
in En
| MEDLINE
| ID: mdl-33675755
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Peptides, Cyclic
/
Complement C3
/
Complement Inactivating Agents
/
Geographic Atrophy
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Am J Ophthalmol
Year:
2021
Document type:
Article
Affiliation country:
United States